CSL +2.06%: biotech and plasma protein demand resilient
CSL Limited's +2.06% gain to $352.14 makes it the clear session winner among ASX large-caps. CSL operates in plasma protein therapies, vaccine development, and blood-product manufacturing — a largely defensive portfolio with increasing benefit from AI-assisted drug discovery interest lifting biotech valuations globally. Rask Media has been running CSL vs. Cochlear (COH) value comparisons this week — CSL's revenue and earnings visibility makes it the more institutionally favored super (superannuation) allocation within healthcare. CSL at $352.14 is approaching 2024 highs and represents the clearest defensive growth story on the ASX when China iron ore demand worry is depressing the mining sector.
Read at Rask Media ↗